{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:34:41Z","timestamp":1791362081057,"version":"4.3.1"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T00:00:00Z","timestamp":1358208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1038\/nrcardio.2012.196","type":"journal-article","created":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T12:43:07Z","timestamp":1358253787000},"page":"125-134","source":"Crossref","is-referenced-by-count":88,"title":["Targeting the renin\u2013angiotensin\u2013aldosterone system in heart failure"],"prefix":"10.1038","volume":"10","author":[{"given":"Chim C.","family":"Lang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan D.","family":"Struthers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,15]]},"reference":[{"key":"BFnrcardio2012196_CR1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","volume":"14","author":"JJV McMurray","year":"2012","unstructured":"McMurray, J. J. V.  et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 14, 803\u2013869 (2012).","journal-title":"Eur. J. Heart Fail."},{"key":"BFnrcardio2012196_CR2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMcp0909392","volume":"362","author":"JJV McMurray","year":"2010","unstructured":"McMurray, J. J. V. Systolic heart failure. N. Engl. J. Med. 362, 228\u2013238 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2012196_CR3","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1001\/jama.2010.748","volume":"303","author":"H Bueno","year":"2010","unstructured":"Bueno, H.  et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993\u20132006. JAMA 303, 2141\u20132147 (2010).","journal-title":"JAMA"},{"key":"BFnrcardio2012196_CR4","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/eurheartj\/ehq426","volume":"32","author":"BA Borlaug","year":"2011","unstructured":"Borlaug, B. A. & Paulus, W. J. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur. Heart J. 32, 670\u2013679 (2011).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio2012196_CR5","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","volume":"33","author":"LC van Vark","year":"2012","unstructured":"van Vark, L. C.  et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur. Heart J. 33, 2088\u20132097 (2012).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio2012196_CR6","doi-asserted-by":"crossref","unstructured":"SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293\u2013302 (1991).","DOI":"10.1056\/NEJM199108013250501"},{"key":"BFnrcardio2012196_CR7","doi-asserted-by":"crossref","unstructured":"The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N. Engl. J. Med. 316, 1429\u20131435 (1987).","DOI":"10.1056\/NEJM198706043162301"},{"key":"BFnrcardio2012196_CR8","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","volume":"327","author":"MA Pfeffer","year":"1992","unstructured":"Pfeffer, M. A.  et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 327, 669\u2013677 (1992).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2012196_CR9","doi-asserted-by":"crossref","unstructured":"The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145\u2013153 (2000).","DOI":"10.1056\/NEJM200001203420301"},{"key":"BFnrcardio2012196_CR10","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rohde, R. D. for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329, 1456\u20131462 (1993).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2012196_CR11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrcardio.2011.172","volume":"9","author":"N Koitabashi","year":"2012","unstructured":"Koitabashi, N. & Kass, D. A. Reverse remodeling in heart failure\u2014mechanisms and therapeutic opportunities. Nat. Rev. Cardiol. 9, 147\u2013157 (2012).","journal-title":"Nat. Rev. Cardiol."},{"key":"BFnrcardio2012196_CR12","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/cvr\/cvn333","volume":"81","author":"Y Sun","year":"2009","unstructured":"Sun, Y. Myocardial repair\/remodelling following infarction: roles of local factors. Cardiovasc. Res. 81, 482\u2013490 (2009).","journal-title":"Cardiovasc. Res."},{"key":"BFnrcardio2012196_CR13","first-page":"325","volume":"147","author":"JP Cleutjens","year":"1995","unstructured":"Cleutjens, J. P., Verluyten, M. J., Smiths, J. F. & Daemen, M. J. Collagen remodeling after myocardial infarction in the rat heart. Am. J. Pathol. 147, 325\u2013338 (1995).","journal-title":"Am. J. Pathol."},{"key":"BFnrcardio2012196_CR14","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1161\/01.CIR.96.11.4065","volume":"96","author":"KT Weber","year":"1997","unstructured":"Weber, K. T. Extracellular matrix remodeling in heart failure. A role for de novo angiotensin II generation. Circulation 96, 4065\u20134082 (1997).","journal-title":"Circulation"},{"key":"BFnrcardio2012196_CR15","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/01.CIR.86.2.431","volume":"86","author":"MA Konstam","year":"1992","unstructured":"Konstam, M. A.  et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 86, 431\u2013438 (1992).","journal-title":"Circulation"},{"key":"BFnrcardio2012196_CR16","doi-asserted-by":"crossref","first-page":"H626","DOI":"10.1152\/ajpheart.1998.275.2.H626","volume":"275","author":"A Goussev","year":"1998","unstructured":"Goussev, A.  et al. Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure. Am. J. Physiol. Heart Circ. Physiol. 275, H626\u2013H631 (1998).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"BFnrcardio2012196_CR17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1161\/01.HYP.18.2.148","volume":"18","author":"M Pahor","year":"1991","unstructured":"Pahor, M.  et al. Enalapril prevents cardiac fibrosis and arrhythmias in hypertensive rats. Hypertension 18, 148\u2013157 (1991).","journal-title":"Hypertension"},{"key":"BFnrcardio2012196_CR18","unstructured":"Elder, D. H., McAlpine-Scott, J., Choy, A. M., Struthers, A. D. & Lang, C. C. Aortic valvular heart disease\u2014is there a place for angiotensin-converting enzyme? Expert Rev. Cardiovasc. Ther. (in press)."},{"key":"BFnrcardio2012196_CR19","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S0735-1097(01)01170-6","volume":"37","author":"J Fielitz","year":"2001","unstructured":"Fielitz, J.  et al. Activation of the cardiac renin\u2013angiotensin system and increased myocardial collagen expression in human aortic valve disease. J. Am. Coll. Cardiol. 37, 1443\u20131449 (2001).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2012196_CR20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jacc.2011.01.063","volume":"58","author":"MA Nadir","year":"2011","unstructured":"Nadir, M. A.  et al. Impact of renin\u2013angiotensin system blockade therapy on outcome in aortic stenosis. J. Am. Coll. Cardiol. 58, 570\u2013576 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2012196_CR21","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/j.jacc.2011.07.043","volume":"58","author":"DH Elder","year":"2011","unstructured":"Elder, D. H.  et al. The impact of renin\u2013angiotensin\u2013aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. J. Am. Coll. Cardiol. 58, 2084\u20132091 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2012196_CR22","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1586\/erc.11.82","volume":"9","author":"DH Elder","year":"2011","unstructured":"Elder, D. H., Lang, C. C. & Choy, A. M. Pacing-induced heart disease: understanding the pathophysiology and improving outcomes. Expert Rev. Cardiovasc. Ther. 9, 877\u2013886 (2011).","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"BFnrcardio2012196_CR23","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.hrthm.2011.11.021","volume":"9","author":"DH Elder","year":"2012","unstructured":"Elder, D. H.  et al. Renin\u2013angiotensin system blockers are associated with reduced mortality and heart failure hospitalization in patients paced for complete atrioventricular block. Heart Rhythm 9, 505\u2013510 (2012).","journal-title":"Heart Rhythm"},{"key":"BFnrcardio2012196_CR24","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1161\/01.CIR.0000147274.83071.68","volume":"110","author":"JJV McMurray","year":"2004","unstructured":"McMurray, J. J. V., Pfeffer, M. A., Swedberg, K. & Dzau, V. J. Which inhibitor of the renin\u2013angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation 110, 3281\u20133288 (2004).","journal-title":"Circulation"},{"key":"BFnrcardio2012196_CR25","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","volume":"355","author":"B Pitt","year":"2000","unstructured":"Pitt, B.  et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the Losartan Heart Failure Survival Study ELITE II. Lancet 355, 1582\u20131587 (2000).","journal-title":"Lancet"},{"key":"BFnrcardio2012196_CR26","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","volume":"374","author":"MA Konstam","year":"2009","unstructured":"Konstam, M. A.  et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374, 1840\u20131848 (2009).","journal-title":"Lancet"},{"key":"BFnrcardio2012196_CR27","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","volume":"349","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer, M. A.  et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 349, 1893\u20131906 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2012196_CR28","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","volume":"360","author":"K Dickstein","year":"2002","unstructured":"Dickstein, K. & Kjekshus, J. the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 360, 752\u2013760 (2002).","journal-title":"Lancet"},{"key":"BFnrcardio2012196_CR29","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/CIRCULATIONAHA.109.192064","volume":"119","author":"M Jessup","year":"2009","unstructured":"Jessup, M.  et al. 2009 focused update: ACCF\/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119, 1977\u20132016 (2009).","journal-title":"Circulation"},{"key":"BFnrcardio2012196_CR30","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"CB Granger","year":"2003","unstructured":"Granger, C. B.  et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362, 772\u2013776 (2003).","journal-title":"Lancet"},{"key":"BFnrcardio2012196_CR31","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","volume":"362","author":"JJV McMurray","year":"2003","unstructured":"McMurray, J. J. V.  et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362, 767\u2013771 (2003).","journal-title":"Lancet"},{"key":"BFnrcardio2012196_CR32","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn, J. N. & Tognoni, G. for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667\u20131675 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2012196_CR33","doi-asserted-by":"crossref","unstructured":"The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547\u20131559 (2008).","DOI":"10.1056\/NEJMoa0801317"},{"key":"BFnrcardio2012196_CR34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cardfail.2007.11.008","volume":"14","author":"R Lakhdar","year":"2008","unstructured":"Lakhdar, R., Al-Mallah, M. H. & Lanfear, D. E. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J. Card. Fail. 14, 181\u2013188 (2008).","journal-title":"J. Card. Fail."},{"key":"BFnrcardio2012196_CR35","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jacc.2011.11.063","volume":"59","author":"K Swedberg","year":"2012","unstructured":"Swedberg, K.  et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J. Am. Coll. Cardiol. 59, 1598\u20131603 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2012196_CR36","doi-asserted-by":"crossref","first-page":"34A","DOI":"10.1016\/0002-9149(93)90243-6","volume":"71","author":"F Zannad","year":"1993","unstructured":"Zannad, F. Angiotensin-converting enzyme inhibitor and spironolactone combination therapy: new objectives in congestive heart failure treatment. Am. J. Cardiol. 71, 34A\u201339A (1993).","journal-title":"Am. J. Cardiol."},{"key":"BFnrcardio2012196_CR37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1071-9164(96)80009-1","volume":"2","author":"AD Struthers","year":"1996","unstructured":"Struthers, A. D. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J. Card. Fail. 2, 47\u201354 (1996).","journal-title":"J. Card. Fail."},{"key":"BFnrcardio2012196_CR38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/hrt.82.1.57","volume":"82","author":"RJ MacFadyen","year":"1999","unstructured":"MacFadyen, R. J., Lee, A. F., Morton, J. J., Pringle, S. D. & Struthers, A. D. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 82, 57\u201361 (1999).","journal-title":"Heart"},{"key":"BFnrcardio2012196_CR39","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/cvr\/26.7.671","volume":"26","author":"CG Brilla","year":"1992","unstructured":"Brilla, C. G. & Weber, K. T. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc. Res. 26, 671\u2013677 (1992).","journal-title":"Cardiovasc. Res."},{"key":"BFnrcardio2012196_CR40","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1006\/jmcc.1994.1098","volume":"26","author":"CG Brilla","year":"1994","unstructured":"Brilla, C. G., Zhou, G., Matsubara, L. & Weber, K. T. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J. Mol. Cell. Cardiol. 26, 809\u2013820 (1994).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"BFnrcardio2012196_CR41","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","volume":"76","author":"CS Barr","year":"1995","unstructured":"Barr, C. S.  et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am. J. Cardiol. 76, 1259\u20131265 (1995).","journal-title":"Am. J. Cardiol."},{"key":"BFnrcardio2012196_CR42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0008-6363(97)00091-6","volume":"35","author":"RJ MacFadyen","year":"1997","unstructured":"MacFadyen, R. J., Barr, C. S. & Struthers, A. D. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc. Res. 35, 30\u201334 (1997).","journal-title":"Cardiovasc. Res."},{"key":"BFnrcardio2012196_CR43","doi-asserted-by":"crossref","unstructured":"The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am. J. Cardiol. 78, 902\u2013907 (1996).","DOI":"10.1016\/S0002-9149(96)00465-1"},{"key":"BFnrcardio2012196_CR44","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt, B.  et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709\u2013717 (1999).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2012196_CR45","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0022-5347(17)67001-0","volume":"114","author":"PC Walsh","year":"1975","unstructured":"Walsh, P. C. & Siiteri, P. K. Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostrate. J. Urol. 114, 254\u2013256 (1975).","journal-title":"J. Urol."},{"key":"BFnrcardio2012196_CR46","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt, B.  et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309\u20131321 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2012196_CR47","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ahj.2010.04.024","volume":"160","author":"M Yamaji","year":"2010","unstructured":"Yamaji, M.  et al. Effect of eplerenone versus spironolactone on cortisol and haemoglobin A1c in patients with chronic heart failure. Am. Heart J. 160, 915\u2013921 (2010).","journal-title":"Am. Heart J."},{"key":"BFnrcardio2012196_CR48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad, F.  et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11\u201321 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2012196_CR49","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink, D. N.  et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 351, 543\u2013551 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2012196_CR50","doi-asserted-by":"crossref","first-page":"c1768","DOI":"10.1136\/bmj.c1768","volume":"340","author":"L Wei","year":"2010","unstructured":"Wei, L., Struthers, A. D., Fahey, T., Watson, A. D. & Macdonald, T. M. Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ 340, c1768 (2010).","journal-title":"BMJ"},{"key":"BFnrcardio2012196_CR51","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","volume":"118","author":"B Pitt","year":"2008","unstructured":"Pitt, B., Bakris, G., Ruilope, L. M., DiCarlo, L. & Mukherjee, R. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 118, 1643\u20131650 (2008).","journal-title":"Circulation"},{"key":"BFnrcardio2012196_CR52","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","volume":"101","author":"CA Farquharson","year":"2000","unstructured":"Farquharson, C. A. & Struthers, A. D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation 101, 594\u2013597 (2000).","journal-title":"Circulation"},{"key":"BFnrcardio2012196_CR53","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/hrt.2003.017368","volume":"90","author":"JE Macdonald","year":"2004","unstructured":"Macdonald, J. E., Kennedy, N. & Struthers, A. D. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 90, 765\u2013770 (2004).","journal-title":"Heart"},{"key":"BFnrcardio2012196_CR54","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ahj.2010.06.049","volume":"160","author":"F Beygui","year":"2010","unstructured":"Beygui, F.  et al. Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. Am. Heart J. 160, 642\u2013648 (2010).","journal-title":"Am. Heart J."},{"key":"BFnrcardio2012196_CR55","unstructured":"US National Library of Medicine. ClinicalTrials.gov\n                    [online]\n                    \n                   (2012)."},{"key":"BFnrcardio2012196_CR56","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1161\/CIRCULATIONAHA.104.503706","volume":"111","author":"A Ouvrard-Pascaud","year":"2005","unstructured":"Ouvrard-Pascaud, A.  et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111, 3025\u20133033 (2005).","journal-title":"Circulation"},{"key":"BFnrcardio2012196_CR57","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1161\/CIRCULATIONAHA.106.634626","volume":"114","author":"F Beygui","year":"2006","unstructured":"Beygui, F.  et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 114, 2604\u20132610 (2006).","journal-title":"Circulation"},{"key":"BFnrcardio2012196_CR58","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1097\/HJH.0b013e3282e9a72d","volume":"25","author":"NC Shah","year":"2007","unstructured":"Shah, N. C., Pringle, S. D., Donnan, P. T. & Struthers, A. D. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. J. Hypertens. 25, 2345\u20132351 (2007).","journal-title":"J. Hypertens."},{"key":"BFnrcardio2012196_CR59","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.jacc.2006.07.049","volume":"48","author":"RG Assomull","year":"2006","unstructured":"Assomull, R. G.  et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J. Am. Coll. Cardiol. 48, 1977\u20131985 (2006).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2012196_CR60","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","volume":"102","author":"F Zannad","year":"2000","unstructured":"Zannad, F., Alla, F., Dousset, B., Perez, A. & Pitt, B. on behalf of the RALES Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 102, 2700\u20132706 (2000).","journal-title":"Circulation"},{"key":"BFnrcardio2012196_CR61","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0735-1097(01)01243-8","volume":"37","author":"KM Yee","year":"2001","unstructured":"Yee, K. M., Pringle, S. D. & Struthers, A. D. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J. Am. Coll. Cardiol. 37, 1800\u20131807 (2001).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2012196_CR62","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1540-8167.2006.00477.x","volume":"17","author":"R Ram","year":"2006","unstructured":"Ram, R. & Van Wagoner, D. R. Aldosterone antagonism as an antiarrhythmic approach for atrial arrhythmias in heart failure. J. Cardiovasc. Electrophysiol. 17, 542\u2013543 (2006).","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"BFnrcardio2012196_CR63","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1161\/01.CIR.0000039104.56479.42","volume":"106","author":"G Suzuki","year":"2002","unstructured":"Suzuki, G.  et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 106, 2967\u20132972 (2002).","journal-title":"Circulation"},{"key":"BFnrcardio2012196_CR64","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","volume":"107","author":"M Hayashi","year":"2003","unstructured":"Hayashi, M.  et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 107, 2559\u20132565 (2003).","journal-title":"Circulation"},{"key":"BFnrcardio2012196_CR65","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/CIRCHEARTFAILURE.109.906909","volume":"3","author":"JE Udelson","year":"2010","unstructured":"Udelson, J. E.  et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ. Heart Fail. 3, 347\u2013353 (2010).","journal-title":"Circ. Heart Fail."},{"key":"BFnrcardio2012196_CR66","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/eurheartj\/ehq426","volume":"32","author":"BA Borlaug","year":"2011","unstructured":"Borlaug, B. A. & Paulus, W. J. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur. Heart J. 32, 670\u2013679 (2011).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio2012196_CR67","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","volume":"27","author":"JG Cleland","year":"2006","unstructured":"Cleland, J. G.  et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur. Heart J. 27, 2338\u20132345 (2006).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio2012196_CR68","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf, S.  et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 362, 777\u2013781 (2003).","journal-title":"Lancet"},{"key":"BFnrcardio2012196_CR69","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie, B. M.  et al. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med. 359, 2456\u20132467 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2012196_CR70","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2012.14785","volume":"308","author":"LH Lund","year":"2012","unstructured":"Lund, L. H., Benson, L., Dahlstr\u00f6m, U. & Edner, M. Association between use of renin\u2013angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 308, 2108\u20132117 (2012).","journal-title":"JAMA"},{"key":"BFnrcardio2012196_CR71","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1001\/jama.2012.45418","volume":"308","author":"JC Fang","year":"2012","unstructured":"Fang, J. C. Heart failure therapy: what should clinicians believe? JAMA 308, 2144\u20132146 (2012).","journal-title":"JAMA"},{"key":"BFnrcardio2012196_CR72","unstructured":"ESC Congress News. Spironolactone improves filling pressure in diastolic HF: Aldo-DHF\n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrcardio2012196_CR73","unstructured":"US National Library of Medicine. ClinicalTrials.gov\n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrcardio2012196_CR74","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00125-008-0972-5","volume":"51","author":"K Swaminathan","year":"2008","unstructured":"Swaminathan, K.  et al. Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia 51, 762\u2013768 (2008).","journal-title":"Diabetologia"},{"key":"BFnrcardio2012196_CR75","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/0003-4819-141-10-200411160-00007","volume":"141","author":"L Wei","year":"2004","unstructured":"Wei, L., MacDonald, T. M. & Walker, B. R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann. Intern. Med. 141, 764\u2013770 (2004).","journal-title":"Ann. Intern. Med."},{"key":"BFnrcardio2012196_CR76","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1042\/CS20100432","volume":"120","author":"G Nguyen","year":"2011","unstructured":"Nguyen, G. Renin, (pro)renin and receptor: an update. Clin. Sci. (Lond.) 120, 169\u2013178 (2011).","journal-title":"Clin. Sci. (Lond.)"},{"key":"BFnrcardio2012196_CR77","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/MNH.0b013e328040bfab","volume":"16","author":"G Nguyen","year":"2007","unstructured":"Nguyen, G. The (pro)renin receptor: pathophysiological roles in cardiovascular and renal pathology. Curr. Opin. Nephrol. Hypertens. 16, 129\u2013133 (2007).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"BFnrcardio2012196_CR78","doi-asserted-by":"crossref","first-page":"e41404","DOI":"10.1371\/journal.pone.0041404","volume":"7","author":"AM Moilanen","year":"2012","unstructured":"Moilanen, A. M.  et al (Pro)renin receptor triggers distinct angiotensin II-independent extracellular matrix remodeling and deterioration of cardiac function. PLoS ONE 7, e41404 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrcardio2012196_CR79","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10741-011-9262-2","volume":"17","author":"NF Schroten","year":"2012","unstructured":"Schroten, N. F.  et al. New roles for renin and prorenin in heart failure and cardiorenal crosstalk. Heart Fail. Rev. 17, 191\u2013201 (2012).","journal-title":"Heart Fail. Rev."},{"key":"BFnrcardio2012196_CR80","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.107.108845","volume":"52","author":"DL Feldman","year":"2008","unstructured":"Feldman, D. L.  et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 52, 130\u2013136 (2008).","journal-title":"Hypertension"},{"key":"BFnrcardio2012196_CR81","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1517\/13543784.10.3.417","volume":"10","author":"ND Fisher","year":"2001","unstructured":"Fisher, N. D. & Hollenberg, N. K. Is there a future for renin inhibitors? Expert Opin. Investig. Drugs 10, 417\u2013426 (2001).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"BFnrcardio2012196_CR82","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/00003088-200847080-00002","volume":"47","author":"S Vaidyanathan","year":"2008","unstructured":"Vaidyanathan, S., Jarugula, V., Dieterich, H. A., Howard, D. & Dole, W. P. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin. Pharmacokinet. 47, 515\u2013531 (2008).","journal-title":"Clin. Pharmacokinet."},{"key":"BFnrcardio2012196_CR83","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ejheart.2007.09.002","volume":"9","author":"A Seed","year":"2007","unstructured":"Seed, A.  et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur. J. Heart Fail. 9, 1120\u20131127 (2007).","journal-title":"Eur. J. Heart Fail."},{"key":"BFnrcardio2012196_CR84","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1097\/HJH.0b013e32833d01ae","volume":"28","author":"JH van Esch","year":"2010","unstructured":"van Esch, J. H.  et al. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. J. Hypertens. 28, 2145\u20132155 (2010).","journal-title":"J. Hypertens."},{"key":"BFnrcardio2012196_CR85","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","volume":"1","author":"JJV McMurray","year":"2008","unstructured":"McMurray, J. J. V.  et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail. 1, 17\u201324 (2008).","journal-title":"Circ. Heart Fail."},{"key":"BFnrcardio2012196_CR86","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/eurheartj\/ehq522","volume":"32","author":"SD Solomon","year":"2011","unstructured":"Solomon, S. D.  et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur. Heart J. 32, 1227\u20131234 (2011).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio2012196_CR87","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/eurjhf\/hfr034","volume":"13","author":"B Pitt","year":"2011","unstructured":"Pitt, B.  et al. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. Eur. J. Heart Fail. 13, 755\u2013764 (2011).","journal-title":"Eur. J. Heart Fail."},{"key":"BFnrcardio2012196_CR88","unstructured":"Novartis. Media releases: Novartis announces termination of ALTITUDE study with Rasilez\u00ae\/Tekturna\u00ae in high-risk patients with diabetes and renal impairment\n                    [online]\n                    \n                  , (2011)."},{"key":"BFnrcardio2012196_CR89","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/ndt\/gfn721","volume":"24","author":"HH Parving","year":"2009","unstructured":"Parving, H. H.  et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol. Dial. Transplant. 24, 1663\u20131671 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrcardio2012196_CR90","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving, H. H.  et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204\u20132213 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2012196_CR91","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/eurjhf\/hfq212","volume":"13","author":"H Krum","year":"2011","unstructured":"Krum, H.  et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur. J. Heart Fail. 13, 107\u2013114 (2011).","journal-title":"Eur. J. Heart Fail."},{"key":"BFnrcardio2012196_CR92","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/eurjhf\/hfq209","volume":"13","author":"M Gheorghiade","year":"2011","unstructured":"Gheorghiade, M.  et al. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur. J. Heart Fail. 13, 100\u2013106 (2011).","journal-title":"Eur. J. Heart Fail."},{"key":"BFnrcardio2012196_CR93","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/eurjhf\/hfs033","volume":"14","author":"JJV McMurray","year":"2012","unstructured":"McMurray, J. J. V.  et al. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur. J. Heart Fail. 14, 341\u2013343 (2012).","journal-title":"Eur. J. Heart Fail."},{"key":"BFnrcardio2012196_CR94","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/1470320312455271","volume":"13","author":"RA de Boer","year":"2012","unstructured":"de Boer, R. A.  et al. Dual RAAS suppression: recent developments and implications in light of the ALTITUDE study. J. Renin Angiotensin Aldosterone Syst. 13, 409\u2013412 (2012).","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"BFnrcardio2012196_CR95","unstructured":"US National Library of Medicine. ClinicalTrials.gov\n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrcardio2012196_CR96","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1161\/CIRCULATIONAHA.108.767202","volume":"117","author":"ND Fisher","year":"2008","unstructured":"Fisher, N. D., Jan Danser, A. H., Nussberger, J., Dole, W. P. & Hollenberg, N. K. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 117, 3199\u20133205 (2008).","journal-title":"Circulation"},{"key":"BFnrcardio2012196_CR97","unstructured":"US National Library of Medicine. ClinicalTrials.gov\n                    [online]\n                    \n                  , (2009)."},{"key":"BFnrcardio2012196_CR98","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1161\/HYPERTENSIONAHA.109.148619","volume":"55","author":"JP Forman","year":"2010","unstructured":"Forman, J. P., Williams, J. S. & Fisher, N. D. Plasma 25-hydroxyvitamin D and regulation of the renin\u2013angiotensin system in humans. Hypertension 55, 1283\u20131288 (2010).","journal-title":"Hypertension"},{"key":"BFnrcardio2012196_CR99","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/ki.2008.408","volume":"74","author":"M Freundlich","year":"2008","unstructured":"Freundlich, M.  et al. Suppression of renin\u2013angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 74, 1394\u20131402 (2008).","journal-title":"Kidney Int."},{"key":"BFnrcardio2012196_CR100","unstructured":"US National Library of Medicine. ClinicalTrials.gov\n                    [online]\n                    \n                  , (2010)."},{"key":"BFnrcardio2012196_CR101","doi-asserted-by":"publisher","unstructured":"Mangiafico, S., Costello-Boerrigter, L., Andersen, I. A., Cataliotti, A. & Burnett, J. C. Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur. Heart J. \n                    http:\/\/dx.doi.org\/10.1093\/eurheartj\/ehs262\n                    \n                  .","DOI":"10.1093\/eurheartj\/ehs262"},{"key":"BFnrcardio2012196_CR102","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00004872-199207000-00002","volume":"10","author":"EG Bevan","year":"1992","unstructured":"Bevan, E. G.  et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J. Hypertens. 10, 607\u2013614 (1992).","journal-title":"J. Hypertens."},{"key":"BFnrcardio2012196_CR103","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0140-6736(91)90397-8","volume":"338","author":"CC Lang","year":"1991","unstructured":"Lang, C. C., Motwani, J., Coutie, W. J. & Struthers, A. D. Influence of candoxatril on plasma brain natriuretic peptide in heart failure. Lancet 338, 255 (1991).","journal-title":"Lancet"},{"key":"BFnrcardio2012196_CR104","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1365-2125.1997.00545.x","volume":"43","author":"G McDowell","year":"1997","unstructured":"McDowell, G.  et al. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br. J. Clin. Pharmacol. 43, 329\u2013332 (1997).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnrcardio2012196_CR105","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s002280050196","volume":"51","author":"M Kentsch","year":"1996","unstructured":"Kentsch, M.  et al. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. Eur. J. Clin. Pharmacol. 51, 269\u2013272 (1996).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"BFnrcardio2012196_CR106","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1161\/hc4001.097191","volume":"104","author":"R Corti","year":"2001","unstructured":"Corti, R., Burnett, J. C. Jr, Rouleau, J. L., Ruschitzka, F. & Luscher, T. F. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 104, 1856\u20131862 (2001).","journal-title":"Circulation"},{"key":"BFnrcardio2012196_CR107","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","volume":"356","author":"JL Rouleau","year":"2000","unstructured":"Rouleau, J. L.  et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 356, 615\u2013620 (2000).","journal-title":"Lancet"},{"key":"BFnrcardio2012196_CR108","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer, M.  et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106, 920\u2013926 (2002).","journal-title":"Circulation"},{"key":"BFnrcardio2012196_CR109","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","volume":"17","author":"JB Kostis","year":"2004","unstructured":"Kostis, J. B.  et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am. J. Hypertens. 17, 103\u2013111 (2004).","journal-title":"Am. J. Hypertens."},{"key":"BFnrcardio2012196_CR110","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjp.0707641","volume":"153","author":"RM Fryer","year":"2008","unstructured":"Fryer, R. M.  et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br. J. Pharmacol. 153, 947\u2013955 (2008).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrcardio2012196_CR111","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","volume":"50","author":"J Gu","year":"2010","unstructured":"Gu, J.  et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor\u2013neprilysin inhibitor (ARNi). J. Clin. Pharmacol. 50, 401\u2013414 (2010).","journal-title":"J. Clin. Pharmacol."},{"key":"BFnrcardio2012196_CR112","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","volume":"375","author":"LM Ruilope","year":"2010","unstructured":"Ruilope, L. M.  et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375, 1255\u20131266 (2010).","journal-title":"Lancet"},{"key":"BFnrcardio2012196_CR113","first-page":"A19378","volume":"122","author":"Z Kobalava","year":"2010","unstructured":"Kobalava, Z.  et al. First experience with concomitant AT1 and neprilysin (NEP 24.11) inhibition with LCZ696 in patients with chronic heart failure [abstract]. Circulation 122, A19378 (2010).","journal-title":"Circulation"},{"key":"BFnrcardio2012196_CR114","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","volume":"380","author":"SD Solomon","year":"2012","unstructured":"Solomon, S. D.  et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380, 1387\u20131395 (2012).","journal-title":"Lancet"},{"key":"BFnrcardio2012196_CR115","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jacc.2005.11.030","volume":"47","author":"Y Iwanaga","year":"2006","unstructured":"Iwanaga, Y.  et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J. Am. Coll. Cardiol. 47, 742\u2013748 (2006).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2012196_CR116","unstructured":"US National Library of Medicine. ClinicalTrial.gov\n                    [online]\n                    \n                   (2012)."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2012.196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2012.196","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2012.196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:49:57Z","timestamp":1684468197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2012.196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,15]]},"references-count":116,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["BFnrcardio2012196"],"URL":"https:\/\/doi.org\/10.1038\/nrcardio.2012.196","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,15]]}}}